Recursion Pharmaceuticals (RXRX) Current Deferred Revenue (2020 - 2026)

Recursion Pharmaceuticals has reported Current Deferred Revenue for 7 years, with the latest figure at $32.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 17.29% year-over-year to $32.8 million; the trailing twelve-month figure through Mar 2026 stood at $32.8 million (down 17.29% YoY), and the FY2025 full-year result was $37.6 million, down 39.12% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $32.8 million, down from $37.6 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $73.1 million in Q2 2023, with the low at $2.5 million in Q1 2022.
• Historically, Current Deferred Revenue has averaged $46.3 million across 5 years, with a median of $46.8 million in 2022.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue sank 75.0% — and 2023, when it jumped 2210.44%.
• Recursion Pharmaceuticals' Current Deferred Revenue stood at $56.7 million in 2022, then sank by 35.79% to $36.4 million in 2023, then soared by 69.57% to $61.8 million in 2024, then plunged by 39.12% to $37.6 million in 2025, then dropped by 12.79% to $32.8 million in 2026.
• The last three Current Deferred Revenue figures came in at $32.8 million (Q1 2026), $37.6 million (Q4 2025), and $47.4 million (Q3 2025), per Business Quant data.